Info

Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 43 (suppl):S-237-S-244, 1993.

Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocy-topenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG [abstr]. Blood 88:626a, 1996.

Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996.

Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001.

Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1-7,1998.

Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.

Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 54:903-924, 1997.

Willey ML, de Denus S, Spinier SA. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis. Pharmacotherapy 22: 492-499, 2002.

Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 28:82-85, 1996.

Management of Intraoperative Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery

0 0

Post a comment